US FDA accepts supplemental new drug application for Jardiance for adults with chronic kidney disease
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Routine tests undertaken by women dropped by 35% in 2020
Subscribe To Our Newsletter & Stay Updated